Emerald Bioventures, LLC - 15 May 2026 Form 4 Insider Report for Galera Therapeutics, Inc. (GRTX)

Reporting relationship: 10%+ Owner
Issuer ticker: GRTX
Reported as of: 15 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 29 May 2026, 16:56:27 UTC
Prior SEC filing: 04 May 2026
Source filing: View source filing
Reporting owner signature: /s/ Timothy Opler, Managing Member

Key filing fact

Emerald Bioventures, LLC filed Form 4 for Galera Therapeutics, Inc. (GRTX) on 29 May 2026.

Key facts

This page summarizes Emerald Bioventures, LLC's Form 4 filing for Galera Therapeutics, Inc. (GRTX).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 29 May 2026, 16:56.

Change

Previous filing in this sequence was filed on 04 May 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (2)

CIK 0002020620 Primary reporting owner

Emerald Bioventures, LLC

Relationship: 10%+ Owner
Address: 555 MADISON AVENUE, SUITE 11D, NEW YORK
Signature: /s/ Timothy Opler, Managing Member
Signature date: 29 May 2026

CIK 0001706867

Opler Timothy

Relationship: 10%+ Owner
Address: 555 MADISON AVENUE, SUITE 11D, NEW YORK
Signature: /s/ Timothy Opler
Signature date: 29 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

GRTX transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +20,813,818
Change %: +52%
Price
Shares after: 61,029,978
Date: 15 May 2026
Ownership: Direct
Footnotes: F1, F2, F3

GRTX transaction

Common Stock

Conversion of derivative security

Transaction value
Shares: +20,813,818
Change %: +52%
Price
Shares after: 61,029,978
Date: 15 May 2026
Ownership: Direct
Footnotes: F1, F2, F3

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

GRTX transaction Derivative

Series B Preferred Stock

Conversion of derivative security

Transaction value
Shares: -20,814
Change %: -100%
Price
Shares after: 0
Date: 15 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 20,813,818
Exercise price
Footnotes: F1, F2, F3

GRTX transaction Derivative

Series B Preferred Stock

Conversion of derivative security

Transaction value
Shares: -20,814
Change %: -100%
Price
Shares after: 0
Date: 15 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 20,813,818
Exercise price
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Pursuant to the Certificate of Designation of Preferences, Rights and Limitations of the Series B Non-Voting Convertible Preferred Stock, as amended ("Certificate of Designation"), no fractional shares were issued upon conversion. In lieu of fractional shares, the Issuer will pay Emerald Bioventures, LLC ("Emerald") an amount in cash equal to the trading value of such fractional shares as of the close of business on the date of the conversion in accordance with the Certificate of Designation.

Footnote F2

This Form 4 is jointly filed by and on behalf of each of Emerald and Timothy Opler. Emerald is the record and direct beneficial owner of the securities reported herein. Mr. Opler is the managing member of Emerald and may be deemed to beneficially own securities owned by Emerald.

Footnote F3

Represents 20,813.8186192892 shares of the Issuer's Series B Non Voting Convertible Preferred Stock (the "Series B Preferred Stock"). On May 15, 2026, the Issuer converted all outstanding Series B Preferred Stock into a number of shares of the Issuer's Common Stock ("Common Stock") calculated based on the Conversion Ratio (defined as 1,000 shares of Common Stock issuable upon the conversion of each share of Series B Preferred Stock), pursuant to and in accordance with the Certificate of Designation. The shares of Series B Preferred Stock have no expiration date.